These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18272489)

  • 1. Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.
    Xiong Q; Sun H; Zhang Y; Nan F; Li M
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3128-33. PubMed ID: 18272489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of ion channel function in deafness-causing KCNQ4 mutants by synthetic channel openers.
    Leitner MG; Feuer A; Ebers O; Schreiber DN; Halaszovich CR; Oliver D
    Br J Pharmacol; 2012 Apr; 165(7):2244-59. PubMed ID: 21951272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
    Padilla K; Wickenden AD; Gerlach AC; McCormack K
    Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants.
    Xiong Q; Sun H; Li M
    Nat Chem Biol; 2007 May; 3(5):287-96. PubMed ID: 17435769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drosophila KCNQ channel displays evolutionarily conserved electrophysiology and pharmacology with mammalian KCNQ channels.
    Cavaliere S; Hodge JJ
    PLoS One; 2011; 6(9):e23898. PubMed ID: 21915266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of ICA-27243 on cloned K(V)7 channels.
    Blom SM; Schmitt N; Jensen HS
    Pharmacology; 2010; 86(3):174-81. PubMed ID: 20714208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.
    Brueggemann LI; Haick JM; Neuburg S; Tate S; Randhawa D; Cribbs LL; Byron KL
    Am J Physiol Lung Cell Mol Physiol; 2014 Mar; 306(6):L476-86. PubMed ID: 24441871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence determinants of subtype-specific actions of KCNQ channel openers.
    Wang AW; Yang R; Kurata HT
    J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
    Tatulian L; Delmas P; Abogadie FC; Brown DA
    J Neurosci; 2001 Aug; 21(15):5535-45. PubMed ID: 11466425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of KCNQ channel modulators on the M-type potassium current in primate retinal pigment epithelium.
    Pattnaik BR; Hughes BA
    Am J Physiol Cell Physiol; 2012 Mar; 302(5):C821-33. PubMed ID: 22135213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
    Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
    J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
    Schenzer A; Friedrich T; Pusch M; Saftig P; Jentsch TJ; Grötzinger J; Schwake M
    J Neurosci; 2005 May; 25(20):5051-60. PubMed ID: 15901787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
    Zhou P; Yu H; Gu M; Nan FJ; Gao Z; Li M
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8726-31. PubMed ID: 23650395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents.
    Yeung S; Schwake M; Pucovský V; Greenwood Ia
    Br J Pharmacol; 2008 Sep; 155(1):62-72. PubMed ID: 18536747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
    Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
    Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M channel enhancers and physiological M channel block.
    Linley JE; Pettinger L; Huang D; Gamper N
    J Physiol; 2012 Feb; 590(4):793-807. PubMed ID: 22155935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional and behavioral signatures of Kv7 activator drug subtypes.
    Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
    Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.
    Vervaeke K; Gu N; Agdestein C; Hu H; Storm JF
    J Physiol; 2006 Oct; 576(Pt 1):235-56. PubMed ID: 16840518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XE991 and Linopirdine Are State-Dependent Inhibitors for Kv7/KCNQ Channels that Favor Activated Single Subunits.
    Greene DL; Kang S; Hoshi N
    J Pharmacol Exp Ther; 2017 Jul; 362(1):177-185. PubMed ID: 28483800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomic basis for therapeutic activation of neuronal potassium channels.
    Kim RY; Yau MC; Galpin JD; Seebohm G; Ahern CA; Pless SA; Kurata HT
    Nat Commun; 2015 Sep; 6():8116. PubMed ID: 26333338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.